How do you counsel patients with homologous recombination repair proficient tumors already on niraparib maintenance therapy, prior to the FDA restriction?
Answer from: at Academic Institution
In the NOVA trial, the PFS benefit for the BRCAwt/HRP patient sub-group was approximately 3 months. Given this small improvement in PFS, prior to the FDA restriction, I always had a risk/benefit discussion with patients reviewing this small benefit and whether the benefit outweighs the risks of trea...
Sign in or Register to read more
Answer from: at Community Practice
Same as before and not dependent on the agents – so same advice for Olaparib and rucaparib maintenance. Most of the biomarker-negative patients will demonstrate progression on therapy in a relatively short time period but the assessment of HR proficiency by current testing methodology has fals...